Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
64°
Sunny
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Jaguar Health Inc
(NQ:
JAGX
)
1.250
-0.010 (-0.79%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Jaguar Health Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Jaguar Health Subsidiary Napo Pharmaceuticals Signs License Agreement with its Italian Subsidiary, Napo EU S.p.A., to Develop and Commercialize Crofelemer and Lechlemer in Europe
August 19, 2021
Per the terms of the agreement, Napo Pharmaceuticals will receive an upfront payment of $10 million payable in two installments following the anticipated merger of Napo EU and Dragon SPAC S.p.A. and is...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health Subsidiary Announces Completion of Additional Preclinical Study of Lechlemer (NP-300), the Company's Human Drug Product Candidate for Diarrhea Relief from Cholera and Other Acute Infectious Diarrhea
August 17, 2021
In support of planned Investigational New Drug application for lechlemer, Napo Pharmaceuticals, Jaguar's wholly owned subsidiary, received comprehensive animal toxicity preclinical services supported...
From
Jaguar Health, Inc.
Via
AccessWire
Topics
Death
Exposures
Death
Product Safety
Jaguar Health, Inc. Reports 2021 Second Quarter Financial Results
August 13, 2021
Second quarter 2021 Mytesi® net and gross sales were approximately $0.4 million and approximately $4.9 million Company transitioning to primarily selling Mytesi directly through selected specialty...
From
Jaguar Health, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Product Safety
Jaguar Health Announces Time Change for Friday, August 13th Investor Webcast to 8:00 AM Eastern Time
August 10, 2021
Registration link for webcast appears below Company plans to file Q2 2021 10-Q on August 13, 2021 SAN FRANCISCO, CA / ACCESSWIRE / August 10, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health to Host Investor Webcast Friday, August 13th at 8:30 AM Eastern Time Regarding Q2 2021 Financials & Business Updates
August 10, 2021
- Registration link for webcast appears below - Company plans to file Q2 2021 10-Q on August 13, 2021 - Jaguar kicks off educational awareness contest in honor of African Traditional Medicine Day SAN...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health Announces Adjournment of Annual Meeting of Stockholders Until Friday, September 3, 2021 and Encourages All Shareholders to Vote
August 06, 2021
Based on a preliminary review of votes cast, over 75% have voted in favor of Proposals 2, 3, 4 & 6 Meeting scheduled to reconvene September 3, 2021 at 8:30 AM Pacific Standard Time to provide time to...
From
Jaguar Health, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Product Safety
Regulatory
REMINDER FROM JAGUAR HEALTH: Innovators with Jane King Interview with Lisa Conte to Air During Jaguar Investor Webcast on Thursday, July 29, 2021 at 8:30 AM Eastern to Provide Business Updates
July 28, 2021
Registration link for webcast appears below SAN FRANCISCO, CA / ACCESSWIRE / July 28, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) issued a reminder today that an Innovators with Jane King interview of...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health Announces that Innovators with Jane King Interview with Lisa Conte will Air During Jaguar Investor Webcast on Thursday, July 29, 2021 at 8:30 AM Eastern to Provide Business Updates
July 26, 2021
Registration link for webcast appears below SAN FRANCISCO, CA / ACCESSWIRE / July 26, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) announced today that an Innovators with Jane King interview of Lisa Conte,...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 23, 2021
SAN FRANCISCO, CA / ACCESSWIRE / July 23, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ('Jaguar' or the 'Company') announced today that effective July 15, 2021, the Company granted nonstatutory stock...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Napo EU S.p.A., Jaguar Health's Italian Subsidiary, and Dragon SPAC S.p.A. Announce Close of 8,830,000 Euro Dragon SPAC Financing
July 19, 2021
Napo EU, the identified target of Dragon SPAC, seeks to develop plant-based crofelemer to potentially treat orphan disease - short bowel syndrome (crofelemer has received orphan-drug designation from...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health Announces Completion of Investigator-Initiated Phase 2 HALT-D Study Evaluating Mytesi (Crofelemer) for Prevention and Prophylaxis of Diarrhea in Breast Cancer Patients
July 14, 2021
Abstract of study results submitted by the third-party investigators to December 2021 San Antonio Breast Cancer Symposium SAN FRANCISCO, CA / ACCESSWIRE / July 14, 2021 / Jaguar Health, Inc....
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health Announces Adjournment of Annual Meeting of Stockholders Until Friday, August 6, 2021 and Encourages All Shareholders to Vote
July 09, 2021
Based on a preliminary review of votes cast, over 74% have voted in favor of Proposals 2, 3, 4 & 6 Meeting scheduled to reconvene August 6, 2021 at 8:30 AM Pacific Standard Time to provide time to...
From
Jaguar Health, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Product Safety
Regulatory
Jaguar Health Set to Join Russell Microcap Index
June 23, 2021
Jaguar kicks off educational awareness contest about medicinal plants SAN FRANCISCO, CA / ACCESSWIRE / June 23, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that...
From
Jaguar Health, Inc.
Via
AccessWire
Topics
Derivatives
Exposures
Derivatives
Product Safety
Jaguar Health Announces Adjournment of Annual Meeting of Stockholders Until Friday, July 9, 2021 and Encourages All Shareholders to Vote
June 11, 2021
Based on a preliminary review of votes cast, over 76% have voted in favor of Proposals 2, 3, 4 & 6 Meeting scheduled to reconvene July 9, 2021 at 8:30 AM Pacific Standard Time to provide time to reach...
From
Jaguar Health, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Product Safety
Regulatory
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 04, 2021
SAN FRANCISCO, CA / ACCESSWIRE / June 4, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that effective May 27, 2021, the Company granted nonstatutory stock options...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
REMINDER: Innovators with Jane King Webcast Interview with Jaguar Health CEO Lisa Conte & Dragon SPAC Founding Sponsor Josh Mailman to Take Place Thursday, June 3, 2021 at 8:30 AM Eastern
June 02, 2021
Registration link for webcast appears below SAN FRANCISCO, CA / ACCESSWIRE / June 2, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") issued a reminder today that an Innovators with...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Napo EU S.p.A., Jaguar Health’s Italian Subsidiary, Provides Updates on Plans to Pursue Conditional Marketing Authorization in the EU
June 01, 2021
Jaguar & Dragon SPAC announce initial funding of $10.8 million into Dragon SPAC Napo EU to focus initially on conditional approval for an important orphan indication, short bowel syndrome (SBS), a...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
COVID-19
Product Safety
Jaguar Health & Dragon SPAC Announce Initial Funding of US$10.8 Million into Dragon SPAC
June 01, 2021
Napo EU S.p.A., named target of Dragon SPAC, provides update on plan to pursue conditional marketing authorization for crofelemer in EU Equita Group S.p.A., a leading Italian based investment bank,...
From
Jaguar Health, Inc.
Via
AccessWire
Topics
Initial Public Offering
Exposures
Product Safety
Securities Market
Napo Pharmaceuticals, Jaguar Health’s Subsidiary, Bolsters Management Team with Appointment of Darlene Horton, M.D. as Chief Medical Officer
May 26, 2021
SAN FRANCISCO, CA / ACCESSWIRE / May 26, 2021 / Napo Pharmaceuticals Inc., the wholly-owned subsidiary of Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), announced today the appointment...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health and Napo Pharmaceuticals Provide Key Findings from Cancer-related Diarrhea Abstracts Submitted to ASCO for June 2021 Annual Meeting
May 20, 2021
SAN FRANCISCO, CA / ACCESSWIRE / May 20, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the highlights of the abstract regarding patient outcomes associated with...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health Announces the Launch of a New Social Media Channel Dedicated to Reaching the Growing Jaguar Health Community
May 19, 2021
Newly created Jaguar Health Community Instagram page introduces jaguar-themed contest SAN FRANCISCO, CA / ACCESSWIRE / May 19, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"),...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health Provides Updates on Canalevia (Crofelemer), the First Plant-based Prescription Medicine Under Development for Chemotherapy-induced Diarrhea in Dogs and Exercise-induced Diarrhea in Dogs
May 18, 2021
Canalevia would be first and only FDA-approved plant-based medicine for dogs that suffer from diarrhea during chemotherapy Canalevia will be available by fourth quarter 2021, if conditionally approved...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health, Inc. Reports 2021 First Quarter Financial Results
May 17, 2021
First quarter 2021 Mytesi gross sales and net sales were approximately $4.6 million and approximately $1.2 million, increases of 250% and 43%, respectively Company to host investor webcast Monday, May...
From
Jaguar Health, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Product Safety
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 14, 2021
SAN FRANCISCO, CA / ACCESSWIRE / May 14, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that effective May 12, 2021, the Company granted nonstatutory stock options...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health Announces Adjournment of Annual Meeting of Stockholders Until Friday, June 11, 2021 and Encourages All Shareholders to Vote
May 14, 2021
Based on a preliminary review of votes cast, over 80% have voted in favor of Proposals 2, 3, 4 & 6 Meeting scheduled to reconvene June 11, 2021 at 8:30 AM Pacific Standard Time to provide time to reach...
From
Jaguar Health, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Product Safety
Regulatory
Jaguar Health to Host Investor Webcast Monday, May 17th at 8:30 AM Eastern Time Regarding Q1 2021 Financials & Business Updates
May 11, 2021
Webcast registration link appears below Company plans to file Q1 2021 10-Q on May 17, 2021 SAN FRANCISCO, CA / ACCESSWIRE / May 11, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company")...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health Announces $10.8 Million Registered Direct Offering for the Benefit of Napo EU Business Plan
April 29, 2021
Company terminates at-the-market (ATM) financing program SAN FRANCISCO, CA / ACCESSWIRE / April 29, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced it has entered...
From
Jaguar Health, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Product Safety
Regulatory
Jaguar Health and Napo Pharmaceuticals Announce Title of Abstract Regarding Patient Outcomes Associated with Cancer Therapy-Related Diarrhea Accepted for Poster Presentation at the American Society of Clinical Oncology 2021 Annual Meeting
April 29, 2021
SAN FRANCISCO, CA / ACCESSWIRE / April 29, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced the title of the abstract regarding patient outcomes associated with cancer therapy-related diarrhea...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
REMINDER FROM JAGUAR HEALTH: Innovators with Jane King Webcast Interview to Take Place Friday, April 23, 2021 at 8:30 AM Eastern to Provide a Business Overview of Napo EU S.p.A., Jaguar’s New Italian Subsidiary
April 21, 2021
Registration link for webcast interview appears below SAN FRANCISCO, CA / ACCESSWIRE / April 21, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") issued a reminder today about the...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health Announces Innovators with Jane King Webcast Interview to Take Place Friday, April 23, 2021 at 8:30 AM Eastern to Provide a Business Overview of Napo EU S.p.A., the Company's New Italian Subsidiary
April 19, 2021
Registration link for webcast interview appears below Company premiers Napo EU's new logo and branding, now live on Napoeu.com website SAN FRANCISCO, CA / ACCESSWIRE / April 19, 2021 / Jaguar Health,...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.